Crexendo vs ReposiTrak
Crexendo reported revenue of $68 million in fiscal 2025, 2.9 times ReposiTrak's $23 million in fiscal 2026. Crexendo's revenue grew 12.1% in its latest year, and ReposiTrak's grew 3.0%. Crexendo had an operating margin of 6.9%, against 33.7% at ReposiTrak. Free cash flow was $9 million at Crexendo and $8 million at ReposiTrak. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.
Side by side
| Crexendo | ReposiTrak | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Jun 30, 2026 |
| Revenue | $68M | $23M |
| Revenue growth | 12.1% | 3.0% |
| Revenue growth a year, last 5 years | 33.0% | 2.1% |
| Gross margin | — | 85.8% |
| Operating margin | 6.9% | 33.7% |
| Net margin | 7.4% | 32.5% |
| Free cash flow | $9M | $8M |
| Free cash flow margin | 13.6% | 35.2% |
| Return on capital | 13.3% | 26.7% |
| Net debt to EBITDA | −6.4x | −3.2x |
| Dividends and buybacks | $0M | $3M |
| Change in diluted share count | 5.4% | −0.8% |
| Last close | $5.07 | $6.76 |
| P/E at the last close | 42.3× | 17.3× |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 6 of 8 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CrexendoReposiTrak
Operating margin
Percent of revenue
CrexendoReposiTrak
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CrexendoReposiTrak
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Crexendo and ReposiTrak pages.